Hill-Rom Holdings Inc. (NYSE:HRC) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as $58.92 and last traded at $58.50, with a volume of 267,195 shares traded. The stock had previously closed at $58.04.

Several research analysts have commented on HRC shares. Zacks Investment Research raised shares of Hill-Rom Holdings from a “hold” rating to a “buy” rating and set a $64.00 price objective for the company in a research note on Tuesday, August 9th. KeyCorp reaffirmed a “buy” rating and set a $59.00 price objective on shares of Hill-Rom Holdings in a research note on Thursday, June 23rd. Bank of America Corp. reaffirmed a “buy” rating and set a $69.00 price objective on shares of Hill-Rom Holdings in a research note on Monday, May 2nd. Finally, Morgan Stanley reissued a “hold” rating on shares of Hill-Rom Holdings in a research note on Tuesday, May 3rd. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $61.50.

The stock’s 50 day moving average price is $54.18 and its 200 day moving average price is $50.42. The company has a market capitalization of $3.76 billion and a PE ratio of 59.22.

Hill-Rom Holdings (NYSE:HRC) last released its quarterly earnings results on Thursday, August 4th. The medical technology company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of $0.76 by $0.05. During the same quarter in the prior year, the company posted $0.62 earnings per share. The business had revenue of $655.40 million for the quarter, compared to analysts’ expectations of $647.75 million. The business’s revenue for the quarter was up 38.1% compared to the same quarter last year. On average, equities research analysts predict that Hill-Rom Holdings Inc. will post $3.33 EPS for the current fiscal year.

Other institutional investors have added to or reduced their stakes in the company. Matarin Capital Management LLC acquired a new position in Hill-Rom Holdings during the fourth quarter worth $5,230,000. Trexquant Investment LP acquired a new position in Hill-Rom Holdings during the fourth quarter worth $1,662,000. Marshall Wace LLP acquired a new position in Hill-Rom Holdings during the fourth quarter worth $1,674,000. Finally, Morgan Stanley boosted its position in Hill-Rom Holdings by 203.0% in the fourth quarter. Morgan Stanley now owns 467,877 shares of the medical technology company’s stock worth $22,486,000 after buying an additional 313,445 shares in the last quarter.

Hill-Rom Holdings, Inc is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.